41,869 Shares in Biogen Inc. $BIIB Acquired by SEB Asset Management AB

SEB Asset Management AB acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 41,869 shares of the biotechnology company’s stock, valued at approximately $7,676,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Reflection Asset Management acquired a new stake in Biogen during the 4th quarter worth $25,000. WPG Advisers LLC raised its position in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the last quarter. First Horizon Corp purchased a new position in shares of Biogen in the fourth quarter worth about $30,000. WFA of San Diego LLC purchased a new position in shares of Biogen in the second quarter worth about $32,000. Finally, Root Financial Partners LLC boosted its position in Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

BIIB has been the subject of several research reports. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Mizuho decreased their target price on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research note on Monday, June 15th. HC Wainwright restated a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Oppenheimer upped their price target on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, HSBC reiterated a “reduce” rating and set a $157.00 price objective on shares of Biogen in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average target price of $220.57.

Biogen Price Performance

Biogen stock opened at $203.16 on Wednesday. Biogen Inc. has a 12-month low of $123.38 and a 12-month high of $219.72. The stock has a market cap of $29.99 billion, a P/E ratio of 21.80 and a beta of 0.16. The company has a 50-day moving average price of $199.55 and a 200 day moving average price of $189.45. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts anticipate that Biogen Inc. will post 13.45 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.